Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be a better adjunct treatment to reduce anemia risk than glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes ...

The FDA approved vadadustat (Vafseo) for chronic kidney disease (CKD)-related anemia in adults who have been on dialysis for at least 3 months, developer Akebia Therapeutics announced on Wednesday.

Authors of a recent review explored the complex relationship between CKD, COVID-19, and anemia and offered practice points based on clinical experience. Patients with chronic kidney disease (CKD) ...

Source: Getty Images Addressing anemia in CKD requires a proactive, multifaceted approach, incorporating both conventional and nutritional strategies. Early recognition and intervention are essential ...

Ziltivekimab, an anti-IL-6 ligand antibody, increases iron and other anemia parameters in patients with chronic kidney disease. Ziltivekimab, a novel anti-IL-6 ligand antibody, improves ...

The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment ...

Chronic kidney disease (CKD) is frequently complicated by anaemia, predominantly due to an inadequate production of erythropoietin combined with disruptions in iron metabolism and chronic inflammation ...

We observed that anemia and chronic kidney disease are two frequent conditions among stroke patients. Anemia was independently associated with a decreased one-year survival. Although GFR was ...

Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia Therapeutics’ endgame remains focused on pushing the therapy into a wider ...

SGLT2 inhibitors may be a useful adjunct therapy to reduce anemia risk in patients with type 2 diabetes and early CKD. Anemia risk is lower among patients receiving SGLT2 inhibitors (SGLT2i) compared ...

Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the cheap penny stocks to invest in. On December 1, Akebia Therapeutics ...